Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation

Samira Picht1, Martí Farrera-Sal1, Anna L Hiller2,3

  • 1Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Experimental Immunotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.

Insights

Lipid nanoparticles (LNPs) enhance the function of chimeric antigen receptor (CAR) T cells for autoimmune diseases more effectively than electroporation. This LNP delivery method improves CAR T cell activation and cytotoxic function for transient engineering.

Area of Science:

  • Immunotherapy
  • Cellular Engineering
  • Autoimmune Disease Treatment

Background:

  • Chimeric antigen receptor (CAR) T cells show promise for autoimmune diseases.
  • Current manufacturing challenges (cost, complexity, safety) limit clinical use.
  • Integrating vectors pose risks like insertional mutagenesis and uncontrolled persistence.

Purpose of the Study:

  • Compare *in-vitro*-transcribed (IVT) mRNA delivery platforms (electroporation vs. lipid nanoparticles [LNPs]) for transient CAR T cell engineering.
  • Assess the impact of delivery method on CAR T cell safety, scalability, and function.
  • Provide a framework for developing mRNA-based CAR T cell therapies.

Main Methods:

  • Systematic comparison of electroporation and LNP delivery for IVT mRNA CAR T cell engineering.
  • Utilized primary human T cells.
  • Employed single-cell transcriptomics and functional cell assays.

Main Results:

  • Electroporation achieved higher transfection efficiency and sustained CAR surface expression.
  • LNP delivery reduced stress/senescence signatures and exhaustion markers.
  • LNPs enhanced antigen-driven activation, chemotaxis, and cytotoxic function.

Conclusions:

  • Delivery method significantly impacts CAR T cell transcriptional profiles and function.
  • LNP-mediated delivery is a functionally superior strategy for transient CAR T cell engineering.
  • This approach supports the development of safer, scalable CAR T cell therapies for autoimmune diseases.

Related Concept Videos